Page 96 - Prostate News Today

Tapping into the Million Veteran Program, an ongoing national research effort to learn how genes, lifestyle and military exposures affect the health of participants, researchers at University of California San Diego School of Medicine and the VA San Diego Healthcare System, with colleagues elsewhere, report that a polygenic hazard score based on 290 genetic variants could be an effective tool for predicting genetic risk of lethal prostate cancer.

Cribriform prostate cancer is an aggressive subtype of the disease characterized by its histology, but little is known about its molecular pathways.

Clovis Oncology, Inc. today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations. The presentation... | October 27, 2022

Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival (PFS) in patients with oligometastatic prostate cancer.

Dr. Josie Tenore and Paul Hinds were introduced by a mutual friend in 2017 and hadn't been going out long when she laid down the law: He had to get a physical.

A new study offers a new option to patients with oligometastatic prostate cancer who want relief from hormone therapy without compromising the risk of their disease spreading.

A new randomized study confirms that men with high-risk prostate cancer can be treated with five versus eight weeks of radiation therapy.

A new study finds that sexual side effects of cancer treatment are discussed far less frequently with female patients than with male patients, even when the treatment directly affects sex organs.

An ultrasound scan can be used to detect cases of prostate cancer, according to new research.

In the face of conflicting evidence over the risks and benefits of routine prostate cancer screenings, a large, longitudinal analysis found Veterans Health Administration medical centers with lower prostate screening rates had higher rates of metastatic prostate cancer cases in subsequent years than centers with higher screening rates.